Logo image of WVE

WAVE LIFE SCIENCES LTD (WVE) Stock Fundamental Analysis

NASDAQ:WVE - Nasdaq - SG9999014716 - Common Stock - Currency: USD

8.63  +0.53 (+6.54%)

After market: 8.28 -0.35 (-4.06%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to WVE. WVE was compared to 194 industry peers in the Pharmaceuticals industry. The financial health of WVE is average, but there are quite some concerns on its profitability. WVE is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year WVE has reported negative net income.
WVE had a negative operating cash flow in the past year.
In the past 5 years WVE always reported negative net income.
In the past 5 years WVE always reported negative operating cash flow.
WVE Yearly Net Income VS EBIT VS OCF VS FCFWVE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M

1.2 Ratios

WVE has a Return On Assets of -51.46%. This is comparable to the rest of the industry: WVE outperforms 40.21% of its industry peers.
WVE's Return On Equity of -88.27% is in line compared to the rest of the industry. WVE outperforms 43.30% of its industry peers.
Industry RankSector Rank
ROA -51.46%
ROE -88.27%
ROIC N/A
ROA(3y)-53%
ROA(5y)-54.35%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
WVE Yearly ROA, ROE, ROICWVE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 400

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for WVE so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
WVE Yearly Profit, Operating, Gross MarginsWVE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -2K -4K -6K -8K -10K

More info and screens

6

2. Health

2.1 Basic Checks

WVE does not have a ROIC to compare to the WACC, probably because it is not profitable.
WVE has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, WVE has more shares outstanding
There is no outstanding debt for WVE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
WVE Yearly Shares OutstandingWVE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
WVE Yearly Total Debt VS Total AssetsWVE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

Based on the Altman-Z score of 0.03, we must say that WVE is in the distress zone and has some risk of bankruptcy.
WVE has a Altman-Z score of 0.03. This is comparable to the rest of the industry: WVE outperforms 53.09% of its industry peers.
There is no outstanding debt for WVE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 0.03
ROIC/WACCN/A
WACC9.74%
WVE Yearly LT Debt VS Equity VS FCFWVE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

WVE has a Current Ratio of 2.56. This indicates that WVE is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 2.56, WVE perfoms like the industry average, outperforming 44.85% of the companies in the same industry.
A Quick Ratio of 2.56 indicates that WVE has no problem at all paying its short term obligations.
WVE's Quick ratio of 2.56 is in line compared to the rest of the industry. WVE outperforms 49.48% of its industry peers.
Industry RankSector Rank
Current Ratio 2.56
Quick Ratio 2.56
WVE Yearly Current Assets VS Current LiabilitesWVE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

5

3. Growth

3.1 Past

The earnings per share for WVE have decreased strongly by -57.89% in the last year.
Looking at the last year, WVE shows a very negative growth in Revenue. The Revenue has decreased by -14.98% in the last year.
The Revenue has been growing by 46.63% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-57.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-24%
Revenue 1Y (TTM)-14.98%
Revenue growth 3Y38.28%
Revenue growth 5Y46.63%
Sales Q2Q%-55.82%

3.2 Future

The Earnings Per Share is expected to grow by 18.63% on average over the next years. This is quite good.
WVE is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 46.27% yearly.
EPS Next Y-36.26%
EPS Next 2Y-17.6%
EPS Next 3Y3.39%
EPS Next 5Y18.63%
Revenue Next Year9.36%
Revenue Next 2Y6.93%
Revenue Next 3Y35.08%
Revenue Next 5Y46.27%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
WVE Yearly Revenue VS EstimatesWVE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M
WVE Yearly EPS VS EstimatesWVE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

WVE reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year WVE is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
WVE Price Earnings VS Forward Price EarningsWVE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
WVE Per share dataWVE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-17.6%
EPS Next 3Y3.39%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for WVE!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

WAVE LIFE SCIENCES LTD

NASDAQ:WVE (8/1/2025, 8:11:23 PM)

After market: 8.28 -0.35 (-4.06%)

8.63

+0.53 (+6.54%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)07-30 2025-07-30/bmo
Earnings (Next)11-10 2025-11-10/bmo
Inst Owners84.98%
Inst Owner Change0.04%
Ins Owners0.53%
Ins Owner Change6.2%
Market Cap1.34B
Analysts83.53
Price Target20.74 (140.32%)
Short Float %12.59%
Short Ratio12.71
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-7.84%
Min EPS beat(2)-10.05%
Max EPS beat(2)-5.63%
EPS beat(4)1
Avg EPS beat(4)28.14%
Min EPS beat(4)-64.24%
Max EPS beat(4)192.48%
EPS beat(8)3
Avg EPS beat(8)31.89%
EPS beat(12)5
Avg EPS beat(12)-22.52%
EPS beat(16)6
Avg EPS beat(16)-14.42%
Revenue beat(2)0
Avg Revenue beat(2)-21.59%
Min Revenue beat(2)-25.7%
Max Revenue beat(2)-17.49%
Revenue beat(4)1
Avg Revenue beat(4)1.93%
Min Revenue beat(4)-144.85%
Max Revenue beat(4)195.76%
Revenue beat(8)3
Avg Revenue beat(8)11.85%
Revenue beat(12)4
Avg Revenue beat(12)2.58%
Revenue beat(16)5
Avg Revenue beat(16)2.81%
PT rev (1m)-3.56%
PT rev (3m)-10.53%
EPS NQ rev (1m)-4.98%
EPS NQ rev (3m)-4.53%
EPS NY rev (1m)-3.75%
EPS NY rev (3m)-7.36%
Revenue NQ rev (1m)-19.45%
Revenue NQ rev (3m)-38.7%
Revenue NY rev (1m)-3.91%
Revenue NY rev (3m)-16.67%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 14.29
P/FCF N/A
P/OCF N/A
P/B 9.12
P/tB 9.12
EV/EBITDA N/A
EPS(TTM)-0.9
EYN/A
EPS(NY)-1.09
Fwd EYN/A
FCF(TTM)-1.29
FCFYN/A
OCF(TTM)-1.28
OCFYN/A
SpS0.6
BVpS0.95
TBVpS0.95
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -51.46%
ROE -88.27%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-53%
ROA(5y)-54.35%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.37
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 8.56%
Cap/Sales 1%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.56
Quick Ratio 2.56
Altman-Z 0.03
F-Score2
WACC9.74%
ROIC/WACCN/A
Cap/Depr(3y)14.55%
Cap/Depr(5y)13.53%
Cap/Sales(3y)13.04%
Cap/Sales(5y)9.43%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-57.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-24%
EPS Next Y-36.26%
EPS Next 2Y-17.6%
EPS Next 3Y3.39%
EPS Next 5Y18.63%
Revenue 1Y (TTM)-14.98%
Revenue growth 3Y38.28%
Revenue growth 5Y46.63%
Sales Q2Q%-55.82%
Revenue Next Year9.36%
Revenue Next 2Y6.93%
Revenue Next 3Y35.08%
Revenue Next 5Y46.27%
EBIT growth 1Y-71.46%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-18.97%
EBIT Next 3Y-16.01%
EBIT Next 5YN/A
FCF growth 1Y-1563.48%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-1742.53%
OCF growth 3YN/A
OCF growth 5YN/A